Hello, myeloma world. How has your Friday been so far?

We have an eclectic mix of five new myeloma-related research studies that we'd like to discuss with you today.

Three of the studies involve laboratory (preclinical) research, which is the sort of research we often leave to discuss later in these reports. But all three of the laboratory studies we cover today address interesting topics, so we will be looking at them first.

The first laboratory study concerns Darzalex (daratumumab) and the possibility of combining it with an investigational anticancer …

We tried, myeloma world, but we couldn't come up with a short title for today's report.

There were just too many words needed to describe the three research articles that we plan to review with you in this edition of Myeloma Morning.

First, we have an important new study out of Spain that in­ves­ti­gates the sig­nif­i­cance of Bence Jones protein in smol­der­ing multiple myeloma patients.

Next, we turn to a study by researchers in Japan. They in­ves­ti­gate different methods for measuring a person's bone marrow plasma cell per­cent­ages, and how those methods can …

A pleasant Tuesday to you, myeloma world.

We hope your week has started well. We been away for longer than ex­pec­ted, work­ing through some of the more technical details of the articles we discuss in today's Myeloma Morning.

Most of today's report focuses on two research articles that were published last week. Both articles were published in the journal Blood, and both are valuable contributions to what we know about multiple myeloma. As a result, we devote quite a bit of space to summarizing each of the articles.

Those long summaries mean …

A happy Saturday to you, myeloma world.

We hope your weekend has gotten off to an excellent start.

Today's edition of Myeloma Morning focuses primarily on a study that was included in yesterday's list of new myeloma-related research. The study summarizes trends in allogeneic (donor) stem cell transplantation in Europe over the last two decades.

Although the study focuses on European trends, we believe it should be of interest to Beacon readers regardless where they may be. With the global exchange of information related to multiple myeloma, trends in Europe are not …

We're very glad to see you again, myeloma world.

Myeloma Morning was on brief hiatus while we helped with the Beacon's article about the recently published Ninlaro (ixazomib) clinical trial results.

Now that the Ninlaro article has been published, however, it's time to get back to normal Myeloma Morning business.

And there's a lot of it. In fact, there are almost 20 items in the list of new myeloma research at the end of today's report.

We obviously have to pace ourselves a …

Welcome, myeloma world, to the first "Acronym Edition" of Myeloma Morning.

Every major news item in today's report is closely linked with one or more acronyms. Once we realized this – and once we also realized that this will probably happen again in the future – we realized we had to mark the occasion in some special way.

Hence: Acronym Edition.

We have three brief research summaries at the beginning of today's report, followed by an extended Q&A.

The first two research summaries are mainly for readers interested in the biology of …

Hello, myeloma world. We hope your week has started well.

We have one main item on the agenda for today's edition of Myeloma Morning.

In particular, we want to discuss a topic that is the focus of the only article in our daily list of new myeloma-related research publications, included at the end of this report.

The topic of that article is monoclonal gammopathy of renal significance (MGRS).

Now, most Beacon readers probably have heard of monoclonal gam­mop­athy of undetermined significance (MGUS), an early stage of multiple myeloma that …